Minapharm Pharmaceuticals results, Q3 2023
Net profit, assets, equity and cash flow for Q3 2023, against the same period a year earlier, from the published financial statements.
Net profit5.45 millionEGP · −97.0% vs the same period a year earlier
Total assets8.01 billionEGP · +46.7% vs the same period a year earlier
Shareholders' equity3.39 billionEGP · +43.9% vs the same period a year earlier
Operating cash flow-4.5 millionEGP · −104.1% vs the same period a year earlier
In short
- Minapharm Pharmaceuticals's net profit for Q3 2023 was about 5.45 million EGP, down −97.0% from 184 million EGP in Q3 2022.
- Total assets at the end of Q3 2023 were about 8.01 billion EGP, and shareholders' equity about 3.39 billion EGP.
- Operating cash flow for Q3 2023 was negative at 4.5 million EGP.
Key lines against the same period a year earlier
This periodQ3 2022Change
Net profit5.45 million184 million−97.0%
Gross profit385 million447 million−13.8%
Total assets8.01 billion5.46 billion+46.7%
Total liabilities4.62 billion3.1 billion+48.9%
Shareholders' equity3.39 billion2.36 billion+43.9%
Total liabilities and equity8.01 billion5.46 billion+46.7%
Operating cash flow-4.5 million109 million−104.1%
Investing cash flow-242 million-292 million+17.1%
Financing cash flow136 million159 million−14.4%
Net change in cash-110 million-23.33 million−371.5%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Minapharm Pharmaceuticals's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy